Gilead Sciences Inc
GILDHealthcare|Drug Manufacturers - General|USA
$140.13
+0.42 (+0.30%)
DCF (FCF)
$82.91
Earnings Power
$67.72
About
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Stock Price
+24.7%(1Y)
Pipeline Summary
539 total trials107
Phase 1
173
Phase 2
117
Phase 3
73
Phase 4
Active: 32Completed: 336Withdrawn: 17NOT_YET_RECRUITING: 8Terminated: 72Recruiting: 44Unknown: 22NO_LONGER_AVAILABLE: 1APPROVED_FOR_MARKETING: 6ENROLLING_BY_INVITATION: 1
Active Trials (76)
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
Phase 3Active
Enrollment: 1,021 participants
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
NCT05833867Localized Muscle Invasive Bladder Urothelial Carcinoma
Phase 1Recruiting
Enrollment: 20 participants
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
NCT07210125HIV
Phase 4Active
Enrollment: 75 participants
Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS
NCT05814432Disseminated Histoplasma Capsulatum Infection
Phase 3Recruiting
Enrollment: 279 participants
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095Advanced Upper Gastrointestinal Tract Adenocarcinoma
Phase 3Active
Enrollment: 1,040 participants
BioScore
7.4/10
Buy
Ownership
Recent Insider Trades
O'Day Daniel PatrickSELL
2026-03-2710,000 shares @ $136.82
Dickinson Andrew DSELL
2026-03-163,000 shares @ $144.23
Mercier JohannaSELL
2026-03-163,000 shares @ $144.23
O'Day Daniel PatrickSELL
2026-02-2710,000 shares @ $144.79
Mercier JohannaSELL
2026-02-1728,000 shares @ $154.44
Recent News
2026-04-01 21:00:06
2026-03-31 09:50:29
2026-03-31 00:00:40
2026-03-24 09:24:27
2026-03-24 06:55:21
Data last updated: Apr 7, 2026, 03:34 AM